0001104659-23-111094.txt : 20231024
0001104659-23-111094.hdr.sgml : 20231024
20231024160657
ACCESSION NUMBER: 0001104659-23-111094
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231020
FILED AS OF DATE: 20231024
DATE AS OF CHANGE: 20231024
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZACCARDELLI DAVID
CENTRAL INDEX KEY: 0001627642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38067
FILM NUMBER: 231342772
MAIL ADDRESS:
STREET 1: 300 TRI STATE INTERNATIONAL
STREET 2: SUITE 272
CITY: LINCOLNSHIRE
STATE: IL
ZIP: 60069
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verona Pharma plc
CENTRAL INDEX KEY: 0001657312
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 MORE LONDON RIVERSIDE
CITY: LONDON
STATE: X0
ZIP: SE1 2RE
BUSINESS PHONE: 011-44-0-2032834200
MAIL ADDRESS:
STREET 1: 3 MORE LONDON RIVERSIDE
CITY: LONDON
STATE: X0
ZIP: SE1 2RE
4
1
tm2329036-4_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-10-20
0
0001657312
Verona Pharma plc
VRNA
0001627642
ZACCARDELLI DAVID
3 MORE LONDON RIVERSIDE
LONDON
X0
SE1 2RE
UNITED KINGDOM
1
1
0
0
President and CEO
0
Ordinary Shares
2023-10-20
4
A
0
800000
0
A
17231800
D
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter.
Consists of (i) 6,711,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 838,980 ADSs); and (ii) 10,519,960 Ordinary Shares underlying 1,314,995 ADSs.
/s/ Claire Poll, Attorney-in-fact for David Zaccardelli
2023-10-24